2018 Investor Conference Call, page-12

Slogger I found some information about Hexima. This might be the last information about it...

from Chairman's Letter Annual Report 2014 page 4

"In February 2014 it was announced
that encouraging data had been
generated for an antifungal product
being developed in collaboration with
Hexima Limited and that the next
stage of product development had
been initiated. Acrux subsequently
filed an Australian provisional
patent application to protect the
joint rights of Acrux and Hexima to
the intellectual property resulting
from the collaboration. Hexima
subsequently advised that it
may not wish to further explore
commercialisation of the antifungal
medical product with Acrux.
Acrux considers the best way to
commercialise the technology remains
through our collaboration agreement
with Hexima and is continuing
negotiations with Hexima to achieve
this. Development of a non-melanoma
skin cancer therapeutic project
with Hexima has been suspended
pending commercial resolution for
the development of the antifungal
medical product. In the meantime,
the Acrux team is focusing on other
pipeline opportunities, with several
early investigations underway for
new therapeutic opportunities."